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Background 
The aim of this study was to analyze the relationship between exposure to high-dose 
methotrexate (HDMTX) and tumor response in terms of survival in children with 
osteosarcoma.  
 
Procedure 
This study included 44 patients (479 courses) who received a median dose of 5.92 g/m2 
of MTX (interquartile range (IQR) 2.37 g/m2) in a 4-hr infusion. The mean area under 
the concentration–time curve (AUC) estimated by parametric methods (non-parametric 
expectation maximization, NPEM), and the mean concentration at the end of the 
infusion were considered to be the exposure parameters. Tumor response was recorded 
as disease-free survival (DFS), overall survival (OS), and histologic tumor response. 
The relationship between MTX exposure and survival parameters was analyzed by Cox 
regression. 
 
Results 
The group of 11 patients who were the least exposed to MTX (AUC < 2,400 µmol/Lhr) 
presented a high DFS, probably due to the shorter interval of time between MTX 
courses that led to a higher dose density. In patients with AUC > 2,400 µmol/Lhr, an 
increase in the AUC was related to an increase in the DFS. Significant differences were 
observed in the DFS between patients whose mean AUC was below or above 4,000 
µmol/Lhr (P = 0.024), such that 4,000 µmol/Lhr was considered as the minimum AUC 
to be aimed at for future patients. 
 
Conclusions 
Dose density seems to be an important factor in osteosarcoma response, but this must be 
confirmed in further studies. In order to improve the response to osteosarcoma in 
children, it is recommended that the dose of MTX to be increased such as to obtain an 
AUC higher than 4,000 µmol/Lhr. 
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INTRODUCTION 
 
High-dose methotrexate (HDMTX) is a drug therapy useful in the treatment of diverse 
pediatric tumors such as osteosarcoma [1–5] and acute lymphocytic leukemia (ALL) 
[6,7]. Its role in hematological tumor responses has been widely documented [6–11] but 
few studies describe the relationship between exposure to MTX and tumor response in 
solid tumors such as osteosarcoma. To some extent this reflects the difficulty in 
measuring responses in solid tumors due to delayed growth in time following 
Gompertzian kinetics and the clonal heterogeneity of the tumor, which generates 
different responses to chemotherapy [12]. 
 
Different studies have questioned the role of HDMTX in the treatment of osteosarcoma 
[13,14]. In contrast, various authors have described a significant correlation between 
osteosarcoma tumor response and HDMTX peak level [15–18]. A highly significant 
correlation between tumor response and a MTX serum level greater than 1,000 µmol/L 
at the end of the MTX 4-hr infusion was reported by Delepine et al. [17], and was 
confirmed in 1994 by Graf et al. [3]. Bacci et al. [19] recommended that a serum peak 
of 700 µmol/L or greater should be attained when MTX is infused over 6 hr in order to 
improve the response of osteosarcoma tumors. 
 
To date, no study has correlated the response of osteosarcoma tumors with the area 
under the concentration–time curve (AUC) as the parameter to be considered for 
exposure to MTX. The mechanism of action suggests that MTX exposure is the true 
factor that determines the tumor response in osteosarcoma. It has been shown that the 
cytotoxic effects of HDMTX depend both on MTX concentration and duration of 
exposure [20]. 
 
The aim of this study was to establish a relationship between the exposure to HDMTX 
measured either as the AUC or the peak level, and the response of osteosarcoma tumors 
in terms of patient survival. 
 
 
 
MATERIALS AND METHODS  
 
Patients 
 
Forty-four children with high-grade osteosarcoma (19 males and 25 females) who 
received high-dose MTX therapy between 1986 and 1993 have been studied. The total 
number of MTX courses administered was 479. The inclusion criterion was the 
availability of the relevant data in the patient’s medical charts. 
 
 
Data Collection 
 
The following clinical data were collected by retrospective chart review: age, sex, 
height, weight, lean body weight, body surface area (BSA), diagnosis, pathologic 
subtype of tumor, location of the tumor, presence of distant metastases, creatinine 
clearance estimated by the Schwartz formula [21], significant delay in MTX elimination 
defined as MTX concentration at 24 hr after the end of the infusion (Cp24 hr) >3.5 
µmol/L, and plasma half-life for the initial elimination phase (t1/2α) > 3.5 hr, or MTX 
concentration 48 hr after the end of the infusion (Cp48 hr) ≥ 0.35 µmol/L and plasma 
half-life for the terminal elimination phase (t1/2β) > 12.5 hr (Aldaz et al., personal 
communication); serum creatinine; baseline leukocyte count; volume of hydration; 
lowest recorded urine pH; concurrent use of other drugs (anti-emetics, 
trimethoprim/sulfamethoxazole, penicillins, aminoglucosides, NSAID’s, diuretics, 
cisplatin, carboplatin, or vancomycin); disease-free survival (DFS); and overall survival 
(OS). 
 
 
Chemotherapy Protocol 
 
The chemotherapy regimen administered before the surgery was: cisplatin 40 
mg/m2/day intraarterial (IA), days 1, 2, 3, 21, 22, and 23; doxorubicin 30 mg/m2/day 
intravenous (IV), days 1, 2, 22, and 23; MTX 6 g/m2 IV, days 7,14, 29, and 36; cisplatin 
40 mg/m2/day IA, days 43, 44, and 45. All patients underwent radical excision surgery. 
Two weeks after the surgery the patients received: (A) MTX 6 g/m2 IV; (B) cisplatin 40 
mg/m2/day IV for 3 days; doxorubicin 25 mg/m2/day IV for 3 days; (C) bleomycin 10 
mg/m2/day IV for 3 days; dactinomycin 0.5 mg/m2/day IV for 3 days; ifosfamide 1.5 
g/m2/day IV for 3 days; and Mesna 300 mg/m2 administered before and 4 and 8 hr after 
the ifosfamide. Cycles B and C were repeated every 21 days. Cycle A was administered 
between cycles B and C, days 7 and 14. 
 
 
MTX Administration 
 
The dose of MTX ranged from 3 to 12 g/m2 (median 5.92 g/m2, interquartile range 
(IQR) 2.37 g/m2). MTX dose administered in our hospital increased with the publication 
of new articles that found a significant correlation between MTX peak level and 
survival. Hydration consisted of 3 L/m2/24 hr of 5% dextrose in water with 300 mEq of 
NaHCO3 and 60 mEq of KCl per L. Hydration was begun 12 hr before MTX 
administration and maintained for 3 days. Urine pH was checked throughout the 
hydration period. MTX administration was performed when urine pH was between 7 
and 8 in two consecutive voids and urine flow was at least 120 ml/min. If necessary, 
NaHCO3 dose was adjusted to obtain a urine pH between 7 and 8. MTX dose was 
diluted in 500 ml of 0.9% NaCl and infused over a 4-hr period. The standard leucovorin 
rescue was 15 mg/m2 every 6 hr for 3 days, beginning 24 hr after the end of MTX 
administration. 
 
 
Plasma Samples 
 
MTX concentrations were measured at specific times to determine adequate leucovorin 
rescue therapy or supportive care. High-risk concentrations of MTX had been 
previously determined in our hospital in a preliminary study in pediatric patients (Aldaz 
et al., personal communication): Cp24 hr > 3.5 µmol/L or Cp48 hr > 0.35 µmol/L. 
Therefore, in most cases MTX plasma concentrations were determined at the end of the 
MTX infusion and at 24 and 48 hr. Crom and Evans [22] guidelines for modification of 
leucovorin dosage were followed in patients with high-risk MTX concentrations, at time 
≥ 42 hr after the beginning of MTX infusion. 
Sample Analysis 
 
MTX plasma concentrations were measured by fluorescence polarization immunoassay 
(FPIA) with a TDxFLxTM analyzer (Abbott Laboratories, Abbott Park, IL) [23]. 
 
 
Pharmacokinetic Analysis 
 
Pharmacokinetic parameters of MTX were estimated by parametric (IT2B, Iterative 
Two-stage Bayesian) [24] and non-parametric methods (non-parametric expectation 
maximization, NPEM) [25] using the software package USC*PACK 10.7a (University 
of Southern California, Los Angeles, CA) and assuming a two-compartment 
pharmacokinetic model. First of all, pharmacokinetic parameters were estimated by 
IT2B in order to obtain a range of variability of the parameters and estimate the value of 
σ (intraindividual variability) to be applied on NPEM. The assay error pattern was 
determined by the Jelliffe and Tahani method [26]. The pharmacokinetic parameters 
estimated by NPEM were chosen for their lower log-likelihood, lower entropy, and 
similar predictive performance when compared with that obtained by IT2B. 
Pharmacokinetic parameters estimated were: elimination rate constant (kel); rate 
constants for MTX’s movement from central to peripheral compartment (kcp); and 
peripheral to central (kpc) and volume of distribution for the central compartment (Vc). 
MTX systemic clearance (CL) and AUC were estimated according to the following 
equations [27]: 
  
 CL = kel x Vc      and       AUC = dose/CL 
 
 
Pharmacokinetics–Pharmacodynamics Analysis 
 
As parameters for MTX exposure, the mean peak defined as the mean value of all 
plasma peak values of the patient, and the mean AUC as the mean value of all the 
AUC’s obtained in the patient in each course of MTX were estimated. The different 
values of MTX peak concentrations and AUC for the same patient were very similar in 
the different MTX courses. As parameters for the treatment response, histologic tumor 
response (%), DFS, and OS were recorded. To compare the influence of AUC in 
osteosarcoma response, patients were divided in four groups depending on the value of 
the mean AUC recorded, with 11 patients in each group (group 1: <2,400 µmol/Lhr; 
group 2:2,400–3,675 µmol/Lhr; group 3: 3,700–4,800 µmol/L; group 4: > 4,800 
µmol/Lhr). 
 
 
Statistical Analysis 
 
The relationship between exposure to MTX and survival parameters was analyzed by 
Cox regression. Coxs F-test was applied to compare final events of two groups in terms 
of survival. To compare multiple samples, a nonparametric test that is an extension of 
Gehans generalized Wilcoxon test, Peto and Petos generalized Wilcoxon test, and the 
log-rank test was used. To compare multiple samples two by two, Coxs F-test with 
Bonferroni adjustment [28] was used. Cumulative proportional survival graphs were 
realized by Kaplan–Meier curves. The statistic program used was STATISTICA 
(edition 99, Stat SoftTM, Inc., Tulsa, OK) [29]. The alpha level considered was 0.05 
except in multiple comparisons with Bonferroni adjustment in which a value of 0.05/k 
was used, being k the number of comparisons performed. 
 
 
 
RESULTS 
 
We have studied the relationship between exposure to HDMTX and response of 
osteosarcoma tumors in terms of patient survival in 44 children. The clinical and 
treatment variables for the children, who received a total number of 479 HDMTX 
courses, are listed in Tables I and II. No significant variation was observed in MTX 
doses administered to the same patient in the different MTX courses. 
 
Urine pH lower than 7 was detected only in four MTX courses. In three cases, the acid 
urine pH (5–6.5) resulted in a significant delay in MTX elimination (Cp24 hr > 3.5 
µmol/L and t1/2α > 3.5 hr, or Cp48 hr ≥ 0.35 µmol/L and t1/2β > 12.5 hr). 
 
A large variability was observed in both the mean doses of MTX administered (from 
3.51 to 10.33 g/m2) and in the mean AUC (from 1,073 to 9,266 µmol/Lhr). The DFS 
was 42.50 (64.50) months and the OS 72.50 (52.75) months, both expressed as media 
(IQR). At a follow-up of 5 years, 21 patients (47.7%) remained free of disease and 32 
(72.7%) alive. 
 
The characteristic of the treatments received and the clinical responses of the different 
groups depending on the mean AUC are presented in Table III, and their diagnostics in 
Table IV. No significant differences were found between the four AUC groups in the 
different variables of osteosarcoma prognostics [30], such as the osteosarcoma subtype, 
tumor location, histologic tumor response, sex, age, and MTX dose in g/m2 per week. 
Four patients presented distant metastases at diagnosis considered being a poor 
prognosis factor. However, these patients were evenly distributed between the four 
groups. In Figures 1 and 2 the DFS and the OS of the different AUC groups are shown. 
Highly significant differences were observed in the DFS between the different mean 
AUC groups by Cox regression (P = 0.0055) (Fig. 1), although this was not the case in 
terms of the OS (P=0.33) (Fig. 2). Both the DFS and the OS are correlated [r = 0.68, P < 
0.001; OS (months) = 37,098 + 0,65 x DFS (months)] such that patients with a longer 
DFS, lived longer than those who developed early distant metastases or had a local 
progression of the illness. 
 
In general, an increase in the mean AUC was reflected by an increase in the DFS and in 
the OS. However, an exception was observed in the group exposed to the lowest MTX 
AUC (group 1), that showed a high DFS and OS. The DFS of group 1 was comparable 
to that obtained in the group 4 (P = 0.23). One variable that could explain the response 
observed in group 1 was the shorter interval of time between MTX courses. In this 
group, the mean interval between MTX courses was 28 days while in the rest of the 
groups was about 7 days longer. In the analysis of the relationship between MTX 
exposure and tumor response, this group was analyzed independently in order to avoid 
the possible influence of the interval of time between courses in the results. 
 
In patients with AUC >2,400 µmol/Lhr, a highly significant relationship was found 
between DFS and the AUC (P = 0.0037), and between DFS and the mean peak level    
(P = 0.010) by Cox regression. On the contrary, no significant relationship was detected 
between OS and AUC (P = 0.19) or OS and mean peak level (P = 0.69). By Coxs F-test 
with Bonferroni adjustment, none of the comparisons two by two between groups was 
significant in DFS (P < 0.017): group 2 and 3, P = 0.041; group 3 and 4, P = 0.034; and 
group 2 and 4, P = 0.019. In the same way, none significant differences were detected in 
OS: group 2 and 3, P = 0.038; group 3 and 4, P = 0.019; and group 2 and 4, P = 0.048. 
The group of patients that received the highest MTX exposure (group 4) also presented 
the best histologic tumor response, considered as an index of the response of the tumor 
to chemotherapy prior to surgery, mean 89.29% (SD 13.36). 
 
In patients with AUC > 2,400 µmol/Lhr, significant differences were detected by Coxs 
F-test in DFS considering the mean AUC of 4,000 µmol/Lhr as the cut-off point (P = 
0.024) (Fig. 3). A close and linear correlation was observed between the MTX peak 
concentration and the AUC (Spearman R = 0.91, P < 0.001, Fig. 4), with a highly 
significant relationship between a mean AUC of 4,000 µmol/Lhr and a mean peak 
concentration of 700 µmol/L. 
  
 
 
DISCUSSION 
 
In this study of 44 children with osteosarcoma, a significant relationship was found 
between the DFS and the mean AUC of MTX. The threshold mean AUC where 
significant differences in DFS were detected was a mean AUC value of 4,000 µmol/Lhr. 
 
A high DFS was also observed in the group of patients exposed to the lowest levels of 
MTX (group 1, AUC < 2,400 µmol/Lhr), a result that could not be explained by a 
difference in the prognosis for these patients. Since these 11 patients received the lowest 
mean dose of MTX, media 4.84 (IQR 1.19) g/m2 (Table III), they consequently 
developed less toxic effects than the rest of the patients. This fact allowed the 
administration of MTX courses every 28 days whereas the patients who received higher 
doses frequently developed mucositis, leukopenia, or renal toxicity that delayed the 
administration of MTX course by a mean of 7 days (Table III). Thus, one possible 
explanation for the good response observed in group 1 might be the shorter interval 
between MTX courses, with the importance that it may have in solid tumors response. 
In this group, the dose density (amount of drug administered during a defined period of 
time) was higher although dose intensity (dose administered per cycle) was lower. 
 
The influence of the time interval between MTX ad-ministration on the response 
observed in earlier studies might support this hypothesis. In a study published by Frei et 
al. [31], the response in osteosarcoma was improved by increasing the dose of MTX and 
was made worse by increasing the period of time between MTX administration. The 
French Tumor Study Group [1] found that the delay in MTX course administration was 
a negative factor in the prognosis of osteosarcoma. Bacci et al. [32] have described that 
avoid reductions of doses and/or delays in performing the courses of chemotherapy is 
crucial for outcome in osteosarcoma. Whether shorter intervals between MTX courses 
might improve osteosarcoma response should also be addressed. On the other hand, it 
cannot be disregarded that the high DFS observed in group 1 was due to a different 
exposure to other agents used in the treatment, as cisplatin, doxorubicin, bleomycin, 
dactinomycin, or ifosfamide. Also other factors that were not assessed in the study 
could have contributed to the good response observed. 
 
In those patients with AUC > 2,400 µmol/L, a significant relationship was found 
between DFS and AUC whereby an increase in the mean AUC led to a longer DFS. It 
has been reported that the cytotoxic effects of HDMTX depend on the drug 
concentration and the duration of exposure above a threshold concentration, being the 
duration of exposure the determinant factor once the minimum threshold concentration 
has been achieved [20]. 
 
The threshold mean AUC required to generate significant differences in DFS was a 
mean AUC value of 4,000 µmol/Lhr, which correlates with a peak of 700 µmol/ L. In 
contrast, Graf et al. [3] found that a threshold MTX peak level of 1,000 µmol/L needs to 
be surpassed for MTX treatment in osteosarcoma to be effective. The corresponding 
AUC (4,000 µmol/Lhr) abolished the differences observed in DFS of osteosarcoma. 
They also found a highly significant correlation between MTX peak level and AUC (R 
= 0.66). It can be deduced from the slope of the linear relationship between the AUC 
and the MTX peak level that the concentration was higher in our study than in COSS-80 
[3] and the same values of AUC were obtained with different peak MTX concentrations. 
 
Different MTX peak levels (700 and 1,000 µmol/L) could generate the same AUC 
value. Renal characteristics were not described in the COSS-80 study and therefore it 
was not possible to compare the differences at this level. However, it is worthy noting 
that in 1982, Breithaupt and Küenzlen [33] found that an AUC of 4,000 µmol/Lhr was 
correlated with a peak level of 700 µmol/L in osteosarcoma patients, data that 
correspond with the result obtained in our study. 
 
In an in vitro study in lymphoblasts, Keefe et al. [20] found that exposure of cells to 1 
µmol/L MTX for 36 or 42 hr was significantly more effective than shorter exposures of 
3 or 6 hr at 100 µmol/L. This result can be explained by intracellular metabolism of 
MTX to its polyglutamate derivates, which is related to the cellular retention and 
cytotoxicity of MTX. Polyglutamation of MTX depends on the presence of free 
intracellular MTX. Once an intracellular MTX concentration that maximally inhibits 
dihydrofolate reductase has been reached, polyglutamation is dependent on the duration 
of exposure. For that reason, the continued presence of intracellular MTX has been 
related to the accumulation of intracellular polyglutamates. 
 
The relationship between histologic tumor response and DFS and OS has been 
described in different studies [34]. In our study, OS was significantly longer in patients 
that demonstrated an histologic tumor response over 90% (P = 0.017). The group of 
patients who received the highest exposure of MTX (group 4, AUC > 4,800 µmol/ Lhr) 
presented the highest mean histologic response, mean 89.29% (SD 13.36). This result 
indicates that the higher the MTX exposure, the higher the histologic tumor response 
and consequently the patient survival. 
 
Although in COSS-80 Graf et al. [3] did not find significant differences in DFS with the 
AUC, the threshold peak level of 1,000 µmol/L was correlated with an AUC of 4,000 
µmol/Lhr. The coincidence between the threshold AUC values obtained in our study 
and that of Graf et al., despite the different peak levels, confirms the importance of the 
length of exposure above a critical concentration in the response of osteosarcoma. The 
optimal parameter when considering MTX exposure is the AUC because it reflects the 
real exposure, including both the concentration reached and the time of exposure. When 
the AUC is not available, the peak level can be used due to the high correlation between 
both variables. 
  
The fact that no significant relationship was detected between the OS and patients with 
AUC > 4,000 µmol/Lhr could be explained because of the inherent limitations of the 
survival analysis. This method penalizes the absence of final events (death of the 
patient) and therefore is not able to obtain information from group 4, where only one 
patient died during the period of time of the study. Besides, there were few patients in 
each group (only 11). 
 
 
 
CONCLUSIONS 
 
The results obtained in this study indicate that MTX dose should be adapted in 
osteosarcoma patients in order to obtain an AUC > 4,000 µmol/Lhr in order to improve 
the DFS. Moreover, we have shown that the highest levels of exposure to MTX are 
associated with the highest levels of tumor necrosis. On the other hand, the group that 
was least exposed MTX (AUC < 2,400 µmol/Lhr) showed a high DFS, probably due to 
the higher dose density. Besides dose intensity, dose density seems to be an important 
factor in osteosarcoma response. This must be confirmed in further studies. The 
possibility that other factors could influence this response cannot be disregarded. 
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Table 1. Anthropometric and Clinical Variables (44 Patients) 
Variable Mean SD CV (%) Range 
BSA (m2) 1.40 0.33 23.48 0.67–2.28 
Weight (kg) 46.67 15.99 34.38 15.32–96.43 
WBC (/mm3) 5,167.64 2,286.20 44.24 1,240–15,900 
CrCL (ml/min) 120.80 46.23 38.27 46.23–216.69 
 Median IQR   
Age (years) 14 7 37.88 4–21 
Height (cm) 158 30 14.38 105–192 
SCr (mg/dl) 0.6 0.2 25.25 0.3–1.50 
BSA, body surface area [21]; WBC, baseline leukocyte count; CrCL, 
creatinine clearance estimated by Schwartz formula [21]; SCr, serum 
creatinine; SD, standard deviation; CV, coefficient of variation; IQR, 
interquartile range. 
 
 
 
 
Table 2. Treatment Variables Considering the Mean Values in the Patient in 
the Different Methotrexate (MTX) Courses (44 Patients) 
Variable Median IQR Range 
MTX dose (g/m2) 4.87 2.90 3.51–10.33 
MTX peak level (µmol/L) 450 320 125–1,725 
MTX Cp24 hr (µmol/L) 0.85 1.092 0.04–32 
MTX Cp48 hr (µmol/L) 0.14 0.14 0.0081–6.67 
MTX AUC (µmol/L • h) 3,296 1,748 1,073–9,266 
Volume of hydration (ml/m2/24 hr) 2,352.5 844 1,355–4,687 
Minimum urine pH 7.5 0.5 5–8 
Leucovorin dose (mg/m2) 177.20 71.14 94.46–2,460 
Cp24 hr, MTX plasma concentration 24 hr after the end of the infusion; 
Cp48 hr, MTX plasma concentration 48 hr after the end of the infusion; 
AUC, area under the concentration–time curve. 
 
 
 
 
 
 
 
 
Table 3. Characteristics of the Different AUC Groups                                
(44 Patients, 11 Patients in Each Group) 
Variable Group 1 Group 2 Group 3 Group 4 
Mean AUC (µmol/Lhr) 1,879 (415) 
3,194 
(404) 
4,283 
(386) 
6,253 
(1,167) 
Mean peak level (µmol/L) 381.42 (114.96) 
579.76 
(84.77) 
767.47 
(111.85) 
968.42 
(191.33) 
Mean MTX dose (g/m2) 4.84 (1.19) 
6.30 
(1.12) 
7.99 
(1.12) 
8.87 
(0.75) 
Dose intensity (g/m2/week) 1.20 (0.46) 
1.60 
(0.56) 
1.89 
(0.66) 
2.05 
(0.76) 
Number of MTX courses 10.73 (4.29) 
13.91 
(7.15) 
10.27 
(5.83) 
8.64 
(3.56) 
Mean number of days between  
MTX courses 
28.64 
(8.81) 
35.38 
(15.44) 
33.69 
(11.59) 
35.091 
(9.45) 
Histologic tumor response (%) 70.71 (34.09) 
83.75 
(12.46) 
67.86 
(23.78) 
89.29 
(13.36) 
DFS (months) 63.64 (85.00) 
18.18 
(20.00) 
36.36 
(58.00) 
72.73 
(52.50) 
OS (months) 81.82 (69.00) 
63.64 
(65.00) 
54.55 
(52.00) 
90.91 
(48.33) 
DFS, disease-free survival; OS, overall survival. 
Group 1, mean AUC < 2,400 µmol/Lhr; group 2, mean AUC 2,400–3,675 µmol/Lhr; group 
3, mean AUC 3,700–4,800 µmol/Lhr; group 4, mean AUC > 4,800 µmol/Lhr. Data are 
expressed as median (IQR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Osteosarcoma Subtype and Tumor Location Within 
the Different AUC Groups (44 Patients) 
Mean AUC 
group   Subtype N (%) 
Tumor 
location N (%) 
Group 1 Osteoblastic 6 (54.55) Femur 5 (45.45) 
 Chondroblastic 3 (27.27) Tibia 3 (27.27) 
 Fibroblastic 1 (9.09) Humerus 2 (18.18) 
 Mixed 1 (9.09) Calotte 1 (9.09) 
Group 2 Osteoblastic 6 (54.55) Tibia 5 (45.45) 
 Chondroblastic 2 (18.18) Femur 3 (27.27) 
 Osteogenic 2 (18.18) Humerus 2 (18.18) 
 Telangiectasic 1 (9.09) Fibula 1 (9.09) 
Group 3 Osteoblastic 7 (63.64) Tibia 5 (45.45) 
 Chondroblastic 2 (18.18) Femur 4 (36.36) 
 Mixed 2 (18.18) Humerus 1 (9.09) 
   Costovertebral 1 (9.09) 
Group 4 Osteoblastic 7 (63.64) Femur 6 (54.55) 
 Fibroblastic 2 (18.18) Tibia 3 (27.27) 
 Osteogenic 1 (9.09) Humerus 2 (18.18) 
 Telangiectasic 1 (9.09)   
Group 1, mean AUC<2,400 µmol/Lhr; group 2, mean AUC 2,400– 3,675 µmol/Lhr; 
group 3, mean AUC 3,700–4,800 µmol/L; group 4, mean AUC>4,800 µmol/Lhr. Results 
expressed as number of patients (percentage of patients of the total number of patients in 
each AUC group). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Disease-free survival (DFS) in the mean area under the concentration–time 
curve (AUC) groups. Group 1: mean AUC < 2,400 µmol/ Lhr; group 2: mean AUC 
2,400–3,675 µmol/Lhr; group 3: mean AUC 3,700–4,800 µmol/L; group 4: mean AUC 
> 4,800 µmol/Lhr. 
 
 
 
 
Figure 2. Overall survival (OS) in the mean AUC groups. Group 1: mean AUC < 2,400 
µmol/Lhr; group 2: mean AUC 2,400–3,675 µmol/Lhr; group 3: mean AUC 3,700–
4,800 µmol/L; group 4: mean AUC > 4,800 µmol/Lhr. 
 
 
Figure 3. DFS in the cut-off point of 4,000 µmol/Lhr including patients with mean 
AUC > 2,400 µmol/Lhr (n = 33) (Coxs F, P = 0.024). 
 
 
 
 
 
Figure 4. Correlation between mean AUC and mean methotrexate (MTX) peak 
concentration (44 patients). Spearman R = 0.91, P < 0.001. 
